Form 4: Repligen Corp Director Barthelemy Receives Stock Options and Restricted Stock Units

Director Nicolas Barthelemy of Repligen Corp. reports the acquisition of stock options and restricted stock units.

Summary

• On May 16, 2024, Nicolas Barthelemy, a director of Repligen Corp, acquired 701 restricted stock units, each representing a contingent right to receive one share of Repligen's common stock.
• These restricted stock units vest on the earlier of May 16, 2025, or the date of the next annual meeting of the company's shareholders.
• Barthelemy also acquired stock options (right to buy) for 1,376 shares at an exercise price of $171.03, vesting on the earlier of May 16, 2025, or the date of the next annual meeting of the company's shareholders, and expiring on May 16, 2034.
• Following these transactions, Barthelemy directly owns 3,468 shares of Repligen's common stock and has rights to 1,376 shares through stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and compliance with SEC regulations. It reflects standard compensation practices for directors.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology and life sciences sectors.
• Companies like Thermo Fisher Scientific, Danaher, and Sartorius also utilize similar equity-based compensation plans to align the interests of their directors and executives with those of shareholders.
• The vesting schedules, typically one year or aligned with annual meetings, are also standard practice.

Stakeholder Impact

• The grant of equity-based compensation can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates